The DOI matches its Crossref record; 97 of the 99 references it cites were found in a registry or an index; 72 of the 108 sources its claims cite were checked for support.
Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics
Open accessAbstract
Osteoporosis is a major public health concern affecting millions of people worldwide and resulting in significant economic costs. The condition is characterized by changes in bone homeostasis, which lead to reduced bone mass, impaired bone quality, and an increased risk of fractures. The pathophysiology of osteoporosis is complex and multifactorial, involving imbalances in hormones, cytokines, and growth factors. Understanding the cellular and molecular mechanisms underlying osteoporosis is essential for appropriate diagnosis and management of the condition. This paper provides a comprehensive review of the normal cellular and molecular mechanisms of bone homeostasis, followed by an in-depth discussion of the proposed pathophysiology of osteoporosis through the osteoimmunological, gut microbiome, and cellular senescence models. Furthermore, the diagnostic tools used to assess osteoporosis, including bone mineral density measurements, biochemical markers of bone turnover, and diagnostic imaging modalities, are also discussed. Finally, both the current pharmacological and non-pharmacological treatment algorithms and management options for osteoporosis, including an exploration of the management of osteoporotic fragility fractures, are highlighted. This review reveals the need for further research to fully elucidate the molecular mechanisms underlying the condition and to develop more effective therapeutic strategies.
Overview
CoChat Summary
TL;DR
This narrative review synthesizes normal bone homeostasis and proposed osteoimmunological, gut microbiome, and cellular senescence models of osteoporosis, alongside current diagnostic and treatment approaches. It emphasizes DEXA-based BMD diagnosis, bone turnover markers, and pharmacologic/non-pharmacologic management, while calling for further research into molecular mechanisms and better therapies.
Key findings
- Osteoporosis affects over 14 million people in the US and over 200 million globally; one in three women and one in five men aged 50 or over are estimated to suffer osteoporosis-related fragility fractures. The annual economic burden is USD 6.5 trillion across the US, Canada, and Europe, with the US burden projected to reach USD 25.3 billion by 2025.
- The review frames osteoporosis as a multifactorial bone-remodeling imbalance, extending the traditional endocrine model (estrogen deficiency, secondary hyperparathyroidism, vitamin D/calcium imbalance) with osteoimmunological, gut microbiome, and cellular senescence models. Genetic findings include BMD variance up to 80% in twin studies, up to 144 genes linked to BMD variance, and rs11692564 showing a +0.20 SD effect on lumbar spine BMD.
- Diagnosis primarily relies on DEXA BMD: WHO categories are normal > −1 SD t-score, osteopenia between −1 and −2.5 SD, osteoporosis < −2.5 SD, and established osteoporosis < −2.5 SD plus fragility fracture; sensitivity and specificity are close to 90%. Bone turnover markers and FRAX are also discussed, as is novel CT Hounsfield unit screening.
- Treatment findings include calcium and vitamin D supplementation reducing hip fracture risk by 30% and total fracture risk by 12–15%; denosumab in FREEDOM reduced vertebral fractures by 68%, hip fractures by 40%, and non-vertebral fractures by 20% over the first three years; romosozumab in FRAME reduced new vertebral fractures by 73% versus placebo, and ARCH showed a 48% lower risk of new vertebral fractures versus alendronate-only. Prolonged bisphosphonate use (5+ years) is associated with atypical femur fractures, which affect the contralateral leg in 28% of cases.
Methods
- Design: comprehensive narrative review; no primary data collection or systematic review methodology is stated.
- Data/sample: literature on bone homeostasis, osteoporosis pathophysiology, diagnostics, and therapeutics, including human studies and animal models such as rats and mice.
- Analysis: thematic synthesis of cellular and molecular mechanisms, proposed pathophysiologic models, diagnostic tools, and treatment algorithms; no meta-analysis or formal quality appraisal is described.
Limitations
- Stated: the paper concludes that further research is needed to fully elucidate the molecular mechanisms underlying osteoporosis and to develop more effective therapeutic strategies.
- Evident from the text: as a narrative review, it does not report a systematic search strategy, inclusion/exclusion criteria, or risk-of-bias assessment, and its conclusions rely on cited literature rather than new primary data.
- Evident from the text: several pathophysiologic insights derive from animal models (e.g., rat, mouse, germ-free mice), which may not fully translate to human osteoporosis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
49 Valid · 7 Not valid · 16 Not checked · 3 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The prolonged use of these substances alters the balance between bone resorption and bone formation, favoring bone formation at first but then shifting over time to favor bone resorption.”
§ Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics > 5. Treatment Options > 5.3. Orthopedic Management of Fragility Fractures
What the sources say
- Not matchedcites [15] Dovjak, 2020, Osteoporosis: Pathophysiology and therapeutic options, EXCLI J.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Disputedcites [95] Silverman, 2018, Bisphosphonate-related atypical femoral fracture: Managing a rare but serious complication, Cleve Clin. J. Med. sourceExperimental — accuracy not yet measured
The ‘What Is the Underlying Pathophysiology?’ section describes bisphosphonates as antiresorptive drugs that suppress bone turnover. It says prolonged use could suppress turnover too much, not that it shifts the balance toward bone resorption. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
Every source the paper cites for this claim was checked and supports it.
In the paper
“Cline-Smith et al. (2020) further strengthened this model by demonstrating a relationship between the loss of estrogen and the promotion of low-grade T-cell-regulated inflammation [21].”
§ Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics > 3. Osteoporosis Pathophysiology > 3.1. Osteoimmunological Model
What the sources say
- Supportedcites [21] Axelbaum, 2020, Ovariectomy Activates Chronic Low-Grade Inflammation Mediated by Memory T Cells, Which Promotes Osteoporosis in Mice, J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. source
The Introduction states that the authors' studies show how estrogen loss promotes low-grade inflammation by T cells. The Abstract identifies the experimental setting as ovariectomized mice and describes activation of memory T cells. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, it is thought that imbalances in these molecular and cellular processes alter bone homeostasis, driving the pathophysiology of osteoporosis [5,6].”
§ Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics > 1. Introduction
What the sources say
- Supportedcites [5] Gao, Y., Patil, S., and Jia, J. (2021). The Development of Molecular Biology of Osteoporosis. Int. J. Mol. Sci., 22. source
The Introduction (p. 1) says that osteoporosis reflects an imbalance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation, and that molecules coordinate these functions to sustain bone homeostasis. The Conclusions (p. 17) add that disrupted signaling-molecule levels can alter formation or resorption and lead to osteoporosis. (LLM, conf=0.94)
- Supportedcites [6] Aibar-Almazán, A., Voltes-Martínez, A., Castellote-Caballero, Y., Afanador-Restrepo, D.F., del Carcelén-Fraile, M.C., and López-Ruiz, E. (2022). Current Status of the Diagnosis and Management of Osteoporosis. Int. J. Mol. Sci., 23. source
Section 2, “Bone Biology” (page not provided), says that regulating cellular and molecular processes maintains the balance between bone resorption and formation. It states that an imbalance can lead to loss of bone density and mineral homeostasis, resulting in osteoporosis. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The authors found that, in the pathophysiology of rheumatoid arthritis, the stimulation of bone resorption by osteoclasts is exclusively mediated by Th17 cells, which produce IL-17 to stimulate RANKL expression [15,18,19].”
§ Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics > 3. Osteoporosis Pathophysiology > 3.1. Osteoimmunological Model
What the sources say
- Not matchedcites [15] Dovjak, 2020, Osteoporosis: Pathophysiology and therapeutic options, EXCLI J.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [18] Horton, 1972, Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes, Science source
- Partly supportedcites [19] Sato, 2006, Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction, J. Exp. Med. sourceExperimental — accuracy not yet measured
The paper identifies Th17 as the exclusive osteoclastogenic subset among known CD4+ T-cell lineages (p. 2) and reports that Th17-derived IL-17 promotes osteoclastogenesis, potentially by inducing RANKL on supporting cells (p. 5). It does not say that Th17 cells exclusively mediate osteoclast-driven bone resorption in rheumatoid arthritis: the introduction (p. 2) also describes indirect effects mediated by inflammatory cytokines from synovial cells. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
Every source the paper cites for this claim was checked and supports it.
In the paper
“Dysregulation in its signaling pathway leads to changes in bone mass, such as osteoporosis pseudoglioma syndrome, Pyle’s disease, and van Buchem disease [39].”
§ Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics > 3. Osteoporosis Pathophysiology > 3.4. Genetic Component of Osteoporosis
What the sources say
- Supportedcites [39] Costantini, 2019, New Insights into Monogenic Causes of Osteoporosis, Front. Endocrinol. source
The ‘Defects in Bone Cell Function and Bone Remodeling’ section states that dysregulated WNT/β-catenin signaling causes skeletal disorders with both high and low bone mass. It identifies osteoporosis pseudoglioma syndrome and van Buchem disease as examples, and separately describes aberrant WNT regulation in Pyle’s disease. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
35 more claims · 28 with their cited sources checked
Create a free account to see all 75 claims and to verify the 7 references still open.
- It may state two separate claims as one. 25
- Probably not a substantial claim. 16
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics > 5. Treatment Options > 5.2. Pharmacological Treatment Options
“The 2011 international, randomized, placebo-controlled Fracture Reduction Evaluation of Denosumab (FREEDOM) study showed a reduction in fracture incidence of 68% for vertebral fractures, 40% for hip fractures, and 20% for non-vertebral fractures in the first three years in postmenopausal woman taking denosumab [78].”
§ Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics > References
“78. Cummings S.R. San Martin J. McClung M.R. Siris E.S. Eastell R. Reid I.R. Delmas P. Zoog H.B. Austin M. Wang A. Denosumab for prevention of fractures in postmenopausal women with osteoporosis N. Engl. J. Med. 2009 361 756 765”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics > 3. Osteoporosis Pathophysiology > 3.2. Gut Microbiome Model
“Whisner et al. (2016) and Zaiss et al. (2019) recently reported that the consumption of different prebiotic diets (that can be fermented to SCFAs) was associated with an increased GI absorption of dietary calcium [29,30].”
§ Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics > References
“31. Zaiss M.M. Jones R.M. Schett G. Pacifici R. The gut-bone axis: How bacterial metabolites bridge the distance J. Clin. Investig. 2019 129 3018 3028”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics > 5. Treatment Options > 5.2. Pharmacological Treatment Options
“It achieves this by upregulating the Wnt pathway while also acting as an enhancer of RANKL synthesis, thereby downregulating this latter pathway [83,84,85].”
§ Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics > 2. Cellular and Molecular Mechanisms > 2.2. Bone Homeostasis
“RANKL interacts with the RANK receptor (forming the RANKL-RANK complex) on osteoclast precursors, potently inducing differentiation into multinucleated osteoclasts.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics > 3. Osteoporosis Pathophysiology > 3.2. Gut Microbiome Model
“Ding et al. (2019) showed that germ-free mice exhibit increased bone mass, suggesting that a correlation exists between bone homeostasis and the GM [26].”
§ Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics > References
“26. Ding K. Hua F. Ding W. Gut Microbiome and Osteoporosis Aging Dis. 2020 11 438 447”
Citations
Cites
The limited in vitro lifetime of human diploid cell strains
Hayflick, L. (1965) · Experimental Cell Research · doi:10.1016/0014-4827(65)90211-9 · Cited by 5,876
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
An overview and management of osteoporosis
Sözen, T., Özışık, L., & Çalık Başaran, N. (2019) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2016.048 · Cited by 2,262
Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
Cellular senescence and the senescent secretory phenotype: therapeutic opportunities
Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J., & Kirkland, J. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64098 · Cited by 1,774
Sato, K., Suematsu, A., Okamoto, K., Yamaguchi, A., Morishita, Y., Kadono, Y., Tanaka, S., Kodama, T., Akira, S., Iwakura, Y., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061775 · Cited by 1,554
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708322 · Cited by 1,544
The clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Research works printed but not linked: 6
- Feingold, K.R., Anawalt, B., Boyce, A., Blackman, M.R., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., Dungan, K., and Hofland, J. (2023, January 09). The Epidemiology and Pathogenesis of Osteoporosis, Endotext, Available online: http://www.ncbi.nlm.nih.gov/books/NBK279134/.
- Burr, D.B., and Allen, M.R. (2014). Basic and Applied Bone Biology, Academic Press.
- Rowe, P., Koller, A., and Sharma, S. (2023, January 15). Physiology, Bone Remodeling, Available online: http://www.ncbi.nlm.nih.gov/books/NBK499863/.
- Keen, M.U., and Reddivari, A.K.R. (2023, January 22). Osteoporosis in Females, Available online: http://www.ncbi.nlm.nih.gov/books/NBK559156/.
- Varacallo, M., Seaman, T.J., Jandu, J.S., and Pizzutillo, P. (2023, July 26). Osteopenia, Available online: http://www.ncbi.nlm.nih.gov/books/NBK499878/.
- Lowe, D., Sanvictores, T., Zubair, M., and John, S. (2023, January 22). Alkaline Phosphatase, Available online: http://www.ncbi.nlm.nih.gov/books/NBK459201/.
Cited by
Advances in the roles of ATF4 in osteoporosis
Xiao, Y., Xie, X., Chen, Z., Yin, G., Kong, W., & Zhou, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115864 · Cited by 66
Research progress in Alzheimer's disease and bone-brain axis
Zhang, F., & Zhang, W. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102341 · Cited by 67
Artificial Intelligence Applications for Osteoporosis Classification Using Computed Tomography
Ong, W., Liu, R. W., Makmur, A., Low, X. Z., Sng, W. J., Tan, J. H., Kumar, N., & Hallinan, J. T. P. D. (2023) · Bioengineering · doi:10.3390/bioengineering10121364 · Cited by 56
The role of magnesium in the pathogenesis of osteoporosis
Liu, L., Luo, P., Wen, P., & Xu, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1406248 · Cited by 54
Gut microbiota has the potential to improve health of menopausal women by regulating estrogen
Wang, H., Shi, F., Zheng, L., Zhou, W., Mi, B., Wu, S., & Feng, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1562332 · Cited by 52
Metadata
- Authors
- Adejuyigbe, B., Kallini, J., Chiou, D., & Kallini, J. R.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Kallini, Jennifer R.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-09-26
- Volume
- 24
- Issue
- 19
- Pages
- 14583
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10572718
- OpenAlex
- W4387048864
- Cited by
- 148
- References
- 99
- Citations by year
- 2026: 43 · 2025: 68 · 2024: 34 · 2023: 3
- FWCI
- 8.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Medicinal Plant Pharmacodynamics Research
- Keywords
- osteoporosis, bone homeostasis, osteoimmunology, gut microbiota, cellular senescence, bone mineral density, bone turnover markers, osteoporosis diagnosis, osteoporosis treatment, fragility fractures, fracture risk
- MeSH terms
- Bone and Bones, Humans, Osteoporosis, Bone Density, Pathology, Molecular, Osteoporotic Fractures
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics. https://app.cochat.ai/papers/10.3390/ijms241914583
- The paper
- Adejuyigbe, B., Kallini, J., Chiou, D., & Kallini, J. R. (2023). Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241914583
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.